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Abstract. In human health risk assessment (HHRA), oral ingestion of soil can be a major route 
of exposure to many immobile soil contaminants. Development and validation of in vitro 
assays is currently being undertaken to avoid overestimation of pollutants absorbed by the 
human body when calculating total pollutant concentrations in HHRA. In this study, arsenic 
(As) and lead (Pb) bioaccessibility in polluted Australian soils (n = 6) was assessed using three 
in vitro assays: a physiologically based extraction test (PBET), Solubility/Bioavailability 
Research Consortium Assay (SBRC) and Unified Bioaccessibility Research Group Of Europe 
Method (UBM). In vitro results were compared among these three assays and the possible 
causes of their differences were discussed. A bioaccessibility-corrected HHRA was then 
conducted. Bioaccessibility varied greatly among metal(loid)s and methods, and extending the 
three assays from the gastric to the intestinal phase generally resulted in decreased As and Pb 
bioaccessibility. Using these bioaccessibility values, both hazard index (HI) and carcinogenic 
risk (CR) were calculated, and were found to be higher than threshold values in most samples, 
indicating a potential health risk to local inhabitants. 
1.  Introduction  
Soil is the major sink for trace elements released into the environment due to its high metal-
scavenging potential [1]. For that reason, soil contamination is now receiving increasing research 
attention in terms of restoring soil ecosystems and sustainable use. High concentrations of arsenic (As) 
and lead (Pb) have been observed in soils around mining and smelting sites, orchards, agricultural 
lands, and other contaminated areas. As a class 1 carcinogen (i.e., carcinogenic to humans), As has 
adverse health effects, including dermatological and cardiovascular effects, pulmonary disorders, and 
reproductive and neurological effects [2]. As a heavy metal, Pb toxicity is strongest in the nervous 
system; it can severely damage the brain and kidneys and ultimately causes death at high levels [3].  
In vivo animal models (e.g., swine and mouse) have been employed to determine the relative 
bioavailability of As and Pb in soils. Due to the operating time, cost and ethical issues of such 
methods, in vitro assays were developed to assess oral bioaccessibility of metal(loid)s in soils. Oral 
bioaccessibility is defined as the fraction of the contaminant released from the food matrix into the 
digestive juice chime that is available for absorption [4]. In recent years, numerous in vitro assays, 
including the physiologically based extraction test (PBET), Solubility/Bioavailability Research 
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Consortium Assay (SBRC) and Unified Bioaccessibility Research Group of Europe Method (UBM), 
have been applied to assess As and Pb bioaccessibility in contaminated soils.  Bioaccessibility results 
vary significantly with soil/solution ratio, gastric and intestinal pH, solution composition and other 
factors, and so should be compared within and among in vitro assays. 
Within assays, As and Pb bioaccessibility showed large variability between the gastric phase (GP) 
and intestinal phase (IP). Juhasz et al. found that for the SBRC and in vitro gastrointestinal extraction 
(IVG) assays, As bioaccessibility in contaminated soils was reduced in the IP, corresponding to 
reduced soluble Fe from the gastric to IP and suggesting that dissolved As is absorbed by amorphous 
Fe through surface complexation or ligand exchange with surface hydroxyl functional groups [5]. As 
reported by Li et al., Pb bioaccessibility also sharply decreased, to 0.01–20%, on SBRC, PBET, IVG 
and UBM assays, possibly due to Pb sorption to solids at the higher pH of the IP [6]. In addition to 
variability within assays, there is significant variability in As and Pb bioaccessibility values among 
assays. Juhasz et al. compared As bioaccessibility in 12 As-contaminated soils using the SBRC, 
PBET, standardized German In Vitro (DIN) and IVG assays [5]. Their results showed that As 
bioaccessibility, based on the GP in SBRC, is significantly higher than in the PBET, DIN and IVG, 
mainly due to variability in gastric pH. Li et al. compared Pb bioaccessibility among 12 Pb-
contaminated soils using SBRC, PBET, UBM and IVG [6]. Lead bioaccessibility was found to vary 
among assays, with SBRC (3.0–99%) producing significantly higher values than other assays (0.46–
84%) in the GP. However, the reasons for these differences within and among assays remain unclear 
due to a paucity of studies comparing in vitro assays, and future research should address the trends and 
causes of this variability. 
The main objective of this study was to investigate As and Pb bioaccessibility within and among in 
vitro assays in contaminated soils. In six samples from Australia, total As and Pb concentrations and 
bioaccessibility were assessed with the SBRC, PBET and UBM assays, after which a bioaccessibility-
corrected HHRA was conducted to estimate the potential health risk to local inhabitants. 
2.  Materials and methods  
2.1. Contaminated soils 
Surface soil samples (0–20 cm) containing elevated concentrations of As and Pb were collected from 
six locations in Australia, including sites in Victoria (TP39, GA12, GA13, CS005) and New South 
Wales (BHK1) associated with mining activities, and in South Australia (SH15) associated with 
nonferrous slag application [7]. Following collection, the soils were oven dried (105 °C), sieved to 
obtain the ingestible fraction (particle size, < 250 μm), homogenized through end-over-end rotation 
(45 rpm) for 24 h, and then stored at 20 °C until determination of total metal(loid) concentrations and 
bioaccessibility assessment through three in vitro assays. 
2.2. Total concentrations 
Total metal(loid) concentrations were analyzed by pre-digesting 0.2 g of each soil sample (n = 3) 
overnight with 5 mL aqua regia (1:3, 70% HNO3: 36.5% HCl), followed by digestion in a MARS-6 
microwave (CEM, USA) following USEPA method 3051A. Dissolved metal(loid)s were separated 
from the solid residue via syringe filtration (0.45 μm), stored at 4 °C and analyzed by inductively 
coupled plasma mass spectrometry (ICP-MS) (7500ce; Agilent, USA) following EPA Method 6020A. 
2.3. Three in vitro assays 
SBRC is the simplest and most commonly used assay for evaluating the bioaccessibility of As and Pb 
[8]. This assay contains two phases: gastric and intestinal. The gastric solution consists of 0.4 M 
glycine adjusted to pH 1.5 using HCl. Soil is added to the GP at a solid-to-solution ratio of 1:100. 
Once the soil has been added and the pH is within the desired gastric range, the solution is rotated end-
over-end for 1 h. Then, 4 mL of GP solution is collected and centrifuged for 15 min at 4,500 rpm. For 
the small IP, 1.75 g/L bile and 0.5 g/L pancreatin are added and the solution is adjusted to a pH of 7 ± 
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0.20. Once intestinal-phase conditions have been achieved, the sample is placed back on the end-over-
end shaker for 4 h, after which 4 mL small intestinal solution is collected and centrifuged for 15 min at 
7,500 rpm. Following collection of gastric and IP samples, the solutions are filtered (0.45 μm filter) 
and diluted to 50 mL with 1 N HNO3 for ICP-MS analysis.  
PBET is also a two-phase method, and is commonly used for the evaluation of As, Pb and Cd [9]. 
The PBET method differs from SBRC in terms of the solution composition, soil/solution ratio and GP 
pH. For this assay, 0.2 g of soil was extracted in triplicate using 40 mL per L of simulated gastric fluid 
consisting of 1.25 g pepsin, 0.5 g citrate, 0.5 g malate, 420 μL lactic acid, 500 μ acetic acid, 1 mL 
decanol and 1 L ultrapure water. Gastric pH was adjusted to 2.5 using HCl and a pH meter. After 
applying the same end-over-end mixing process for 1 h, 4 mL of supernatant liquor was centrifuged 
for 15 min at 4,500 rpm. For the small IP, 70 mg/L bile salt and 20 mg/L pancreatin were then added 
and the pH was adjusted to 7. The small intestinal solution was subsequently treated in the same way 
as for the SBRC assay and finally diluted to 50 mL with 1 N HNO3 for ICP-MS analysis.  
In contrast to these assays, UBM includes a saliva phase prior to gastro-intestinal extraction, which 
simulates dissolution processes in the mouth. This method yields results that show strong correlations 
with swine data for As, Cd and Pb [10]. The test is carried out on 0.4-g dried and sieved (< 250 μm) 
samples. For each solid sample, two bioaccessible extracts are collected: one at the end of the GP and 
another at the end of the gastro- IP. Four types of digestive fluid are required: saliva (S), gastric fluid 
(G), duodenal fluid (D) and bile (B). All fluids are prepared the day use in the UBM extraction 
procedure. Each fluid constitutes two solutions, one inorganic (I) and one organic (O), in addition to 
specific enzymes. The soil/solution ratio is 1 : 37.5 and the GP pH is 1.2. The small IP pH is 6.5. 
2.4. Data analysis 
The bioaccessibilities (%) of As and Pb were calculated using the following equation [4]: 
100%
μg)digestion( before soilin present t contaminan 
 μg)digestion( during soil from mobilizedt contaminan
 (%)bility Bioaccessi    (1) 
Human health risk assessment (HHRA) for exposure to heavy metals in these contaminated soils 
via oral ingestion was conducted based on the hazard index (HI) and cancer risk estimation. The 
general exposure equations used in this study are based on the recommendations of Health Canada and 
the US Environmental Protection Agency (EPA) [11, 12]. Because As exhibits strong carcinogenic 
potential in humans, the carcinogenic risk (CR) for As was calculated, while noncarcinogenic risks 
were calculated for As and Pb. For exposure assessment, the chronic daily intake (CDI) of individual 
metals from incidental ingestion of soil was calculated using the following equation: 








                                                        (2)
 
where C is the total concentration of the soil metal (mg/kg) and IR is the ingestion rate. According to 
US EPA data, IR for soil was set as 100 mg/day [13]. EF is the exposure frequency (days/year). 
According to the US EPA, EF for soil is 210 days/year; ED is the exposure duration (30 years); WAB is 
adult body weight (70 kg); and TA is the average time. For noncarcinogens, TA = ED; for carcinogens, 
TA = 70 years [13].  
The noncarcinogenic and CRs for individual metals were calculated using the following equations: 
                                          Hazardous Quotient = (CDI × OBA)/ RfD                                                  (3) 
                                               Carcinogenic risk = CDI × OBA×SF                                                   (4) 
where OBA is the oral bioaccessibility of the metal(loid)s, RfD is the reference dose and SF is the 
slope factor. According to the US EPA, the toxicity response (dose response) to As is 0.0003 
mg/(kgˑday) and the SF is 1.5 per mg/kg/day for As [14]. However, the use of a single parameter for 
Pb risk assessment was rejected because this cannot account for different risk scenarios, according to 
land use and the population likely to be exposed, for example. Thus, a Pb risk parameter was 
developed based on the quantitative relationship between blood-Pb and soil-Pb concentrations [15].  
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In a previous study [16], an RfD value of 0.0035 mg/(kgˑday) for Pb was chosen for HHRA, so the 
same value was applied in this study. 
As exposure to two or more pollutants may result in additive or interactive effects, a hazard quotient 
(HQ) can be calculated to generate the HI for a specific receptor/pathway combination, using the 
following equation: 
                                                               iHQ = HI                                                                     (5) 
If HI exceeds 1, noncarcinogenic effects are possible, with a probability that tends to increase as the 
value of HI increases. An HQ > 10 is considered high and chronic risk. Cancer risk exceeding 0.0001 
is considered sufficiently large to warrant remediation efforts [17]. 
2.5. Quality assurance 
Appropriate quality assurance procedures and precautions were followed to ensure the reliability of 
this research. All experimental reagents used were of analytical reagent grade. Milli-Q water was used 
throughout the study. Reagent blanks were used to correct instrument readings. Experiments were 
carried out in triplicate, including acid digestion and in vitro assay experiments. One standard 
reference soil sample, NIST 2710a, and one blank sample were used in each experiment. The recovery 
rate of total NIST 2710a concentrations are 111.6% for As and 88.4% for Pb, which are within the 
acceptable range. 
3.  Results and discussion  
3.1.  Total As and Pb concentrations  
Total As and Pb concentrations are presented in table 1. Total concentrations of As varied between 74 
and 16,000 mg/kg, while those of Pb varied between 140 and 9,400 mg/kg. According to the 
Environment Protection Authority of Australia (2012), all total As concentrations measured herein 
were markedly higher (3.7–790 times) than the threshold value. Only one sample, TP39, had a Pb 
concentration below the threshold of 140 mg/kg, while all others clearly exceeded the threshold (2.2–
31 times). The total high concentrations of As and Pb indicated that these soils were severely 
contaminated and were therefore ideal for estimating gastro-intestinal bioaccessibility and conducting 
HHRA. 






                                                                                                                                        
 
 
3.2.  As and Pb bioaccessibility values based on three in vitro assays 
Figure 1 presents the bioaccessibility data of As and Pb in six Australian soils based on three assays. 
Bioaccessibility varied among the in vitro assays employed. The As bioaccessibility in the GP varied 
from 5.5% to 54% among the three assays. According to the SBRC method, As bioaccessibility in GP 
varied from 11% to 54%; with PBET, it varied from 5.5% to 44%, while with UBM, it was 28% to 
53%; this was higher than with the other two methods for the same four soil samples (SH15, BHK1, 
GA13 and GA12). In the small IP, As bioaccessibility varied from 5.6% to 49%.  
sample name As Pb 
SH15 970  650  
TP39 3000  140  
BHK1 74  9400  
GA13 890  1300  
GA12 520  950 
CS005 16000  970  
Guideline 20 300 
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Figure 1. Arsenic (As) and lead (Pb) bioaccessibility (%) in the gastric phase (GP) and small intestinal 
phase (IP) determined using three methods: Solubility/Bioavailability Research Consortium Assay 
(SBRC), physiologically based extraction test (PBET) and Unified Bioaccessibility Research Group 
Of Europe Method (UBM). 
Using the SBRC method, As bioaccessibility in IP varied from 11% to 40%, while with PBET, it 
varied from 5.6% to 49%; with UBM, it was 10% to 44%, which was higher than with the other two 
methods for the same four soil samples. Sample CS005 generally had the highest bioaccessibility 
value regardless of the assay used, and it also had the highest total As concentration. Samples SH15 
and TP39 also had significantly elevated As bioaccessibility. Compared to GP, As bioaccessibility in 
IP was generally lower. This is because the higher pH in the IP of 7.0 may result in precipitation of 
dissolved Fe as amorphous Fe oxides, reducing the As concentration via adsorption and/or co-
precipitation [18].  
Pb bioaccessibility in GP varied among the three assays, from 2.6% to 77%. With the SBRC 
method, Pb bioaccessibility in GP varied from 9% to 77%. Using PBET, it varied from 2.6% to 39%. 
Meanwhile, with UBM, it was 12% to 63%. The PBET method had markedly lower values than the 
other methods. In IP, Pb bioaccessibility varied from 0.01% to 20%. Using the SBRC method, Pb 
bioaccessibility in IP varied from 0.5% to 14%; with PBET, it varied from 0.01% to 16%, while with 
UBM it was 3% to 19%. Pb bioaccessibility in IP was markedly lower than that in GP, which may be 
due to the higher pH of the small intestinal compartment, which causes chemical precipitation of the 
metals. The bile salts and pancreatin added to simulated small intestinal solution may also contribute 
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3.3.  Comparison  among three in vitro assays 
Compared to PBET, the SBRC assay provided higher As bioaccessibility in the GP. In the IP, 
dissolved As was probably absorbed by precipitated iron oxides, causing a sharp decrease in the small 
IP of the SBRC assay. According to a previous study [5], in vitro assessment (SBRC, IVG, PBET and 
DIN) of the same soils showed that As bioaccessibility varied depending on the methodology 
employed. When the correlation between in vivo As relative bioavailability and in vitro As 
bioaccessibility was assessed, As relative bioavailability could be predicted using the GP or IP of the 
SBRC, IVG, PBET and DIN assays with varying degrees of confidence (R2 = 0.53–0.75), and the in 
vitro assay encompassing the SBRC GP provided the best prediction of in vivo As relative 
bioavailability. The standardized in vitro assay in Europe, the UBM assay, has been shown to 
generally estimate higher As bioaccessibility values in both the GP and small IP compared to the other 
two assays. Despite this difference, comparison of the in vitro and in vivo results indicated that the 
correlation between As bioaccessibility and As relative bioavailability was similar irrespective of the 
in vitro phase used for determination [20]. The UBM that incorporated all phases provided the best in 
vivo–in vitro correlation (slope = 1.08; R2 = 0.59), and thus was considered the most suitable batch 
method for assessing contaminant bioaccessibility developed to date.  
The disparity in Pb bioaccessibility among methods was caused by differences in assay parameters. 
Gastric pH was observed to strongly influence Pb solubility in soils [21], and the lower gastric pH 
used in SBRC (pH 1.5) compared to PBET (pH 2.5) contributed to the higher Pb bioaccessibility 
estimated using SBRC. However, the pH used in UBM (pH 1.2) could not explain its bioaccessibility 
results, which were lower than those of SBRC. Differences in other assay parameters (e.g., 
soil/solution ratio) and gastric fluid components (e.g., chyme composition) were probably responsible 
for the UBM results. According to Van de Wiele et al., less Pb is dissolved under lower soil/solution 
ratio conditions [22]. Low soil/solution ratios may lead to underestimation of Pb bioaccessibility in 
soils due to limited metal solubility [21]. Compared to SBRC (1 : 100), UBM uses a lower soil : 
solution ratio of 1 : 37.5, which might inhibit Pb dissolution from soils, causing lower Pb 
bioaccessibility. Additional components used in the gastric fluids of the three methods (pepsin and 
mucin for UBM, glycine for SBRC, pepsin for PBET) may also have contributed to the variability in 
Pb bioaccessibility [23]. 
3.4.  Human health risk assessment (HHRA) 
Table 2 presents the HQ, HI and CR of the Australian soil samples. CR was only calculated for As.  
4.  Conclusions  
This study focused on the bioaccessibility of As and Pb in contaminated soils from Australia through 
application of three in vitro assays. HHRA was then conducted to estimate the potential health risk to 
local inhabitants. The results indicated that the total concentrations of As and Pb in contaminated 
Australian soil samples from mining-impacted locations and a nonferrous slag application site were 
all higher than the Environment Protection Authority of Australia threshold values, aside from Pb in 
sample TP39, collected in a mining-impacted location. This finding indicates severe contamination, 
which requires bioaccessibility testing as well as HHRA. Bioaccessibility varied greatly among 
different metal(loid)s, and also showed marked variance in the GP and small IP. Compared to PBET, 
the SBRC assay had a higher As bioaccessibility value in the GP, while in the small IP, dissolved As 
was likely absorbed by precipitated iron oxides, causing a sharp decrease in the small IP of this 
assay. In contrast, the PBET assay exhibited an increase in As bioaccessibility from the GP to the IP 
for most soils. The UBM assay generally had higher As bioaccessibility values in both the GP and IP 
compared to the other two assays, and comparison of in vitro and in vivo results indicated that the 
correlation between As bioaccessibility and As relative bioavailability was similar irrespective of the 
in vitro phase used for its determination. Thus, UBM was considered the most suitable batch method 
for assessing contaminant bioaccessibility. Pb bioaccessibility in the IP was generally much lower 
than that in the GP with all methods. However, Pb bioaccessibility in GP varied widely among the 
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three methods: PBET values were always lowest, while four samples had their highest values with 
the UBM method. The disparity in Pb bioaccessibility among methods was caused by differences in 
assay parameters (e.g., pH, soil/solution ratio, and gastric fluid components). HHRA of contaminated 
Australian soils indicated very high risk to human health, regardless of the assay method applied. Use 
of a single parameter for Pb risk assessment was rejected in this study, with a parameter based on the 
quantitative relationship between blood-Pb and soil-Pb concentrations being used instead. Pb risk 
assessment should be further explored and discussed in future studies. 
Table 2. Hazard quotient (HQ), hazard index (HI) and carcinogenic risk (CR)  
of the Australian fine soil samples (values exceeding thresholds are in bold). 
Sample   SBRC PBET UBM Sample   SBRC PBET UBM 
SH15 
HQ 
GP 1.3 1.2 1.4 
GA13 
HQ 
GP 0.41 0.27 0.68 
IP 0.74 0.70 1.2 IP 0.30 0.34 0.59 
HI  2.0 1.9 2.6 HI  0.62 0.61 1.3 
CR 
GP 2.4E-04 2.3E-04 2.7E-04 
CR 
GP 7.1E-05 5.2E-05 1.3E-04 
IP 1.4E-04 1.4E-04 2.3E-04 IP 5.2E-05 6.6E-05 1.1E-04 
CR (total)  3.8E-04 3.7E-04 5.0E-04 CR (total)  1.2E-04 1.2E-04 2.5E-04 
TP39 
HQ 
GP 4.4 3.4 2.4 
GA12 
HQ 
GP 0.27 0.22 0.70 
IP 2.4 1.7 0.83 IP 0.17 0.27 0.46 
HI  6.8 5.1 3.3 HI  0.44 0.49 1.2 
CR 
GP 8.5E-04 6.6E-04 4.7E-04 
CR 
GP 5.3E-05 4.2E-05 1.4E-04 
IP 4.7E-04 3.3E-04 1.6E-04 IP 3.3E-05 5.3E-05 8.9E-05 
CR (total)  1.3E-03 9.9E-04 6.3E-04 CR (total)  8.6E-05 9.4E-05 2.3E-04 
BHK1 
HQ 
GP 0.04 0.01 0.06 
CS005 
HQ 
GP 23 19 22 
IP 0.02 0.01 0.04 IP 17 21 12 
HI  0.06 0.02 0.10 HI  40 40 34 
CR 
GP 7.9E-06 2.2E-06 1.1E-05 
CR 
GP 4.5E-03 3.7E-03 4.3E-03 
IP 4.3E-06 2.2E-06 7.1E-06 IP 3.3E-03 4.1E-03 2.2E-03 
CR (total)  1.2E-05 4.4E-06 1.8E-05 CR (total)  7.8E-03 7.7E-03 6.6E-03 
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